Dermatology firm Veradermics discloses wider loss in US IPO paperwork

Jan 9 (Reuters) - Clinical-stage dermatology company Veradermics filed for an initial public offering in the United States on Friday and reported wider losses for the first nine months of 2025.

The New Haven, Connecticut-based company reported a net loss attributable to common stockholders of about $55.2 million for the nine months ended September 30, compared with a loss of about $20.8 million a year earlier.

Veradermics is developing treatments including VDPHL01, an oral, non-hormonal candidate for pattern hair loss.

It may first seek approval in men before expanding to women, or it may pursue approval in both at the same time, depending on clinical trial timelines, the filing showed.

The company plans to list on the New York Stock Exchange under the symbol "MANE."

Jefferies, Citigroup and Leerink Partners will underwrite the offering.

U.S. IPOs are expected to gain momentum this year if anticipated interest-rate cuts improve risk appetite, potentially encouraging late-stage drugmakers to tap public markets.

Separately, Eikon Therapeutics also filed for a U.S. IPO, along with electrical equipment maker Forgent Power and Bob's Discount Furniture, earlier on Friday.